drugset / Trial / NCT01932970

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

NCT01932970

Phase 3 Completed 158 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).

Timeline

Start
2013-08-12
Primary completion
2014-01-14
Completion
2017-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Etelcalcetide Other / unclassified 5 mg Intravenous